HMPL-A580 / Hutchmed - LARVOL DELTA

Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody (AACR 2026) - "HMPL-A580 demonstrates strong anti-tumor activity in preclinical models and good PK characteristics, supporting further clinical evaluation."

Oncology • Solid Tumor

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 (GlobeNewswire) - "Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate ('ATTC') will be presented....The tumor cells harboring EGFR high expression, EGFR mut or PAM alterations were more sensitive to HMPL-A580. HMPL-A580 showed a strong bystander effect when EGFR-negative cells co-cultured with EGFR-expression cells. In human tumor xenograft models in mice, HMPL-A580, administered intravenously at 1~10 mg/kg once weekly for two weeks, demonstrated a dose / exposure-dependent anti-tumor activity in multiple EGFR-expression models..."

Preclinical • Solid Tumor

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (clinicaltrials.gov) - P1/2 | N=186 | Recruiting | Sponsor: Hutchmed | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

HUTCHMED (China) Limited…announces that it has initiated a Phase I/IIa clinical trial of HMPL-A580, HUTCHMED’s second novel Antibody-Targeted Therapy Conjugate (“ATTC”), in patients with unresectable, advanced or metastatic solid tumors in China and the US. (GlobeNewswire) - "The first patient received the first dose on March 4, 2026."

Trial status • Oncology • Solid Tumor